EFTA00299784.pdf

09/18/2018 16:38 From: INIMINIM Woodson C. Merrell M Uebfax Page: 1/11 FAX COVER SHEET To: Jeffrey Epstein / Lesley From: Lisa Company: Company: Woodson Merrell MD PLLC Fax: Phone: Date: 9/18/2018 Pages w/cover: 11 Subject: 9-14-18 LABCORP (Partial) Lab Re Comments: EFTA00299784 09/10/2010 16:30 From: 3477565616 Woodson C. Merrell M Wehfax Page: 2/11 LabCorp Patient Report Specimen ID: 257-480 2371-0 Acct 31143092 Phone Rte: 68 Control ID: FSB31: 43092 Woodson Merrell EPSTEIN, JEFFREY 44 E67th St 9E 71STST New York NY 10065 NEW YORK W 10021 Patient Details Specimen Details Physician Details DOB:01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRF.LL Age(y/m/d):065/07/25 Date received: 09/15/2018 Referring: Gender. M 55/t Date entered: 09/15/2018 ID: MERFtELL Patient ID: Date reported: 09/18/2018 0610 ET NPI: 1023153509 General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items CBC With Differential/Platelet Comp. Metabolic Panel (14); Urinalysis, Routine; PE+Interp(Rfx IFE),S; Lipid Panel; Iron and TIBC; Testosterone,Free+Weakly Bound; Vitamin 812 and Folate; FSH and Lit C-Reactive Protein, Cardiac; Hemoglobin Ale: Prostate-Specific Ag. Serum; TSH; Vitamin D. 26-Hydroxy; Lipoprotein (a); IGF-1; ANA vt/Reflex; Homocyst(e)ine, Plasma; ProlaCtini Thyroxine (14) Free, Direct. S: Cortlsol; DHEA-Sutfate; Estredlot Uric Acid; Phosphorus; LOH; GOT; Amylase; Ferritin, Serum; Insulin; COICIUM. Ionized, Serum: Fibrinogen Activity: Magnesium, RBC TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAE CBC With Differential/Platelet WBC 5.7 x10E3/uL 3.4 - 10.B 01 RBC 4.90 x10136/uL 4.14 - 5.80 01 Hemoglobin 14.7 g/dL 13.0 - 17.7 01 Hematocrit 42.2 % 37.5 - 51.0 01 MCV 86 fL 79 - 97 01 MCH 30.0 pg 26.6 - 33.0 01 MCHC 34.8 g/dL 31.5 - 35.7 01 RDW 14.6 t 12.3 - 15.4 01 Platelets 242 x1083/uL 150 - 379 01 Neutrophils 50 I Not Estab. 01 Lymphs 37 % Not Estab. 01 Monocytes 5 * Not Estab. 01 Eos 7 * Not Estab. 01 Basos 1 * Not Estab. 01 Neutrophils (Absolute) 2.8 x10E3/uL 1.4 - 7.0 01 Lymphs (Absolute) 2.1 x1083/uL 0.7 - 3.1 01 Monocytes(Absolute) 0.3 x1083/uL 0.1 - 0.9 01 Eos (Absolute) 0.4 x1083/uL 0.0 - 0.4 01 Baso (Absolute) 0.0 x10133/uL 0.0 - 0.2 01 Immature Granulocytes 0 * Not Estab. 01 Immature Grans (Abs) 0.0 x10E3/uL 0.0 - 0.1 01 Comp. Metabolic Panel (14) Glucose 128 High mg/dL 65 - 99 01 Sample is lipamic. This may cause spurious increases in TBili, DBili, AST, ALT, and GIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. Date Issued: 09/1&181053 ET PRELIMINARY REPORT Page 1 of S Tb-5decumemcontainsprivareandcorfidential , tested by state and federal law. 121995-20113 Laboratory Corporation of Americas Holdings II you have received this document in error, Meow WI All Itghb Rained • Enterprise Ripon Version 100 EFTA00299785 09/10/2010 16:38 From: Woodson C. Merrell M Webfax Page: 3/11 ilagorP Patient Report Patient: EPSWN. JOFIIIY Specimen ID:257-480-2371-0 DO8:01/20/1953 Patient ID: Control ID: F5831143092 Date collected: 09/14/2018 1255 uxal TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB BUN 22 mg/dL 8 - 27 01 Creatinine 0.96 mg/dL 0.76 - 1.27 01 eGFR If NonAfricn Am 83 mL/min/1.73 >59 eGFR If Africn Am 95 mL/min/1.73 >59 BUN/Creatinine Ratio 23 10 - 24 Sodium 138 mmol/L 134 - 144 01 Potassium 4.2 mmol/L 3.5 - 5.2 01 Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and UIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. Chloride 102 mmol/L 96 - 106 01 Carbon Dioxide, Total 20 mmol/L 20 - 29 01 Calcium 9.4 mg/dL 8.6 - 10.2 01 Protein, Total 6.7 g/dL 6.0 - 8.5 01 Albumin 4.3 g/dL 3.6 - 4.8 01 Globulin, Total 2.4 g/dL 1.5 - 4.5 A/G Ratio 1.8 1.2 - 2.2 Bilirubin, Total 0.3 mg/dL 0.0 - 1.2 01 Alkaline Phosphatase 71 IU/L 39 - 117 01 AST (SCOT) 26 IU/L 0 - 40 01 The specimen was lipemic. The lipemia was cleared by ultracentrifugation before testing. However HDL, direct LDL, cholesterol and triglyceride (if ordered) were performed prior to ultracentrifugation. ALT (SGPT) 37 IU/L 0 - 44 01 Urinalysis, Routine Urinalysis Gross Exam 01 Specific Gravity 1.027 1.005 - 1.030 01 pH 5.5 5.0 - 7.5 01 Urine-Color Yellow Yellow 01 Appearance Clear Clear 01 WBC Esterase Negative Negative 01 Protein Negative Negative/Trace 01 Glucose Negative Negative 01 Ketones Negative Negative 01 Occult Blood Negative Negative 01 Bilirubin Negative Negative 01 Urobilinogen,Semi-Con 0.2 EU/dL 0.2 - 1.0 01 Nitrite, Urine Negative Negative 01 Microscopic Examination Microscopic follows if indicated. 01 PE+Interp(Rfx IFE),S Will Follow Date issued: 09/18/181053 Et PRELIMINARY REPORT Page? of 5 lit dmument contains private and torelldentittl " otected by state and tedertl 01995-2013 Laboratory Commotion of America* Holdings If you have receNed thedocument in error, oletne call an POP Rewind Enterprise Ripon Versiort 100 EFTA00299786 09/10/2018 16:38 From: Woodson C. Merrell M Wehfax Page: 4/11 LabCorp Patient Report Pattern: EPSTEVUE9FREY Spedmen 10:257-480-2371.0 DOB:01/20/1953 Patient ID: Control ID: F5831143092 Date colkcted:09/I4/2018 1255 Local TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Lipid Panel Cholesterol, Total 234 High mg/dL 100 - 199 01 Triglycerides 2714 Alert mg/dL 0 - 149 01 Results confirmed on dilution. HDL Cholesterol 19 Low mg/dL >39 01 VLDL Cholesterol Cal mg/dL 5 - 40 The calculation for the VLDL cholesterol is not valid when triglyceride level is >400 mg/dL. LDL Cholesterol Cale mg/dL 0 - 99 Triglyceride result indicated is too high for an accurate LDL cholesterol estimation. Iron and TIBC Iron Bind.Cap.(TIBC) 320 ug/dL 250 - 450 UIBC 252 ug/dL 111 - 343 01 Iron 68 ug/dL 38 - 169 01 Iron Saturation 21 t 15 - 55 Testosterone,Free+Weakly Bound Testosterone, Serum 140 Low ng/dL 264 - 916 01 Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCHM 2017,102;1161-1173. PMID: 28324103. Testost., % Free+Weakly Bound Will Follow V 9.0 - 46.0 02 Testosc., F+W Bound Will Follow ng/dL 40.0 - 250.0 Vitamin B12 and Folate Will Follow FSH and LH LH 3.7 mIU/mL 1.7 - 8.6 01 FSH 4.4 mIU/mL 1.5 - 12.4 01 C-Reactive Protein, Cardiac 1.56 mg/L 0.00 - 3.00 01 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 Hemoglobin Alc Hemoglobin Alc 5.5 4.8 - 5.6 01 Please Note: 01 Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.7 ng/mL 0.0 - 4.0 01 Dare Issued. 09/18181053 ET PRELIMINARY REPORT Page 3 of5 The document contalm. white and corfidential beak ' recite by state and federal law. A 1995-2018 Laboratory Corporadon of ArneriCell Holdings If you have rend this document into'', please call All Rights Reserved • Enterprise Report Veniore 100 EFTA00299787 09/10/2010 16:30 From: MISIMO Woodson C. Merrell 11 Yebfax Page: 5/11 ktalbetorP Patient Report Patient: EPSIEIKJEFFREY Specimen ID: 257-S80-2371D 008:01/20/I953 Patient ID: Control ID: F5831143092 Date collected:09/14/2018 1255 Local TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. TSH 1.290 uIU/mL 0.450 - 4.500 01 Vitamin D, 25-Hydroxy 20.2 Low ng/mL 30.0 - 100.0 01 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-0H vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Bolick MP, Hinkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEN. 2011 Jul; 96(7):1911-30. Lipoprotein (a) 20 nmol/L <75 01 Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities. IGF-1 Insulin-Like Growth Factor I 137 ng/mL 49 - 188 02 ANA w/Reflex ANA Direct Negative Negative 01 Homocyst(e)ine, plasma 14.9 umol/L 0.0 - 15.0 01 Prolactin 3.9 Low ng/mL 4.0 - 15.2 01 Thyroxine (T4) Free, Direct, S T4,Frce(Directi 1.05 ng/dL 0.82 - 1.77 01 Cortisol 3.7 ug/dL 01 Cortisol AM 6.2 - 19.4 Cortisol PM 2.3 - 11.9 Date Issueo: 09/18/18 1053 ET PRELIMINARY REPORT Pape 4 of 5 This document contains private and confidereiel health information otected by state and federa Haw. 19952018 Liboratory Corporation of America* Hoklings If you hive received this6000mm in error, Please NI Rights Reserved -Enterprise Report Pollen: 1,00 EFTA00299788 09/18/2818 16:38 From: Woodson C. Merrell M Uebfax Page: 6/11 :l-LabCorp Patient Report Patient: EPSTEIN, JEFFREY Specimen ID: 2574804371-0 D09:0120/1953 Patient ID: Control ID: F5831143092 Date collected: 09/14/2018 1255 L0GI TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB DENA-Sulfate 181.8 ug/dL 30.9 - 295.6 01 Estradiol 28.3 pg/mL 7.6 - 42.6 01 Roche ECLIA methodology Uric Acid Uric Acid 6.8 mg/dL 3.7 - 8.6 01 Please Note: 01 Therapeutic target for gout patients: <6.0 Phosphorus 3.6 mg/dL 2.5 - 4.5 01 LDH 213 IU/L 121 - 224 01 GGT 25 IU/L 0 - 65 01 Amylase 37 U/L 31 - 124 01 Ferritin, Serum Will Follow Insulin 47.2 High uIU/mL 2.6 - 24.9 01 Calcium, Ionised, Serum 5.3 mg/dL 4.5 - 5.6 01 Fibrinogen Activity 330 193 - 507 01 Specimen was ultracentrifuged before testing to remove extreme lipemia. Results should be interpreted with caution. Magnesium, RBC 5.4 mg/dL 4.2 - 6.8 02 Plasma NOT separated from cells; may falsely decrease RBC Magnesium levels. 01 RN LabCorp Raritan Dir. Aracei B Reyes. MD 69 First Avenue. Raritan, NJ 08889-1800 02 BN LabCorp Burlington DO: Wham F Hancock, MD 1447 York Court. Burlington, NC 27215-3361 For inquiries, the phys'cian may contact Branch: 800431-5250 Lab: Date ISSued: 09/18/18 1053 ET PRELIMINARY REPORT Page sas Wsdocument contains pnvate and confidential health informadon tected by state and federal law. 01995-2018 Laboratory Corporaoa of Arnericae Holdings it you have welved thisdocument enrol, *Me cal RiphiAntrad • purpose ReportVaniort 1.00 EFTA00299789 09/10/2018 16:30 From: eilleklin Woodson C. Merrell M Webfax Page: 7/11 NLabCon) Patient Report Specimen ID: 257.480.22320 Acct I: 31143092 Phone: Rte: 68 Control ID: FSA31143092 Woodson Merrell EPSTEIN, JEFFREY 44 E 67th St New York NY 10065 PatientDetails Specimen Details Physician Details 1208:01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: Agefy/rn/d): 065/07/25 Date receive* 09/15/2018 Referring: Gender. M SSW Date entered: 09/15/2018 ID: MERRELL Patient Kr Date reports: 09/16/2018 0808 ET NPI: General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items Ca+PTH Intact TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAE Ca+PTH Intact Calcium 9.5 mg/dL 8.6 - 10.2 01 Specimen received hemolyzed. Clinical correlation indicated. PTH, Intact 71 High pg/ML 15 65 01 Intact PTH 01 Interpretation Intact PTH Calcium (pg/mL) (mg/dL) Normal 15 - 65 8.6 - 10.2 Primary Hyperparathyroidism >65 >10.2 Secondary Hyperparathyroidism >65 <10.2 Non-Parathyroid Hypercalcemia <65 >10.2 Hypoparathyroidism <15 < 8.6 Non-Parathyroid Hypocalcemia 15 - 65 < 8.6 01 RN LabCorp Raritan Dir. Aracei B Reyes, MD 69 First Avenue Raritan NJ 08889-1800 Fee Inquiries, the physician may canted Branch: Lab: Welssued:0WIN180916U FINAL REPORT Page I of 1 This docurront corcalre private and confidential health' hived by state and federal law. O1995.2018 Laboratory Corporation of Americas Holdings if wau have receiveo this document in error, please call All lights Reserved • Fnterprhe Report Venlow 140 EFTA00299790 09/18/2018 16:30 From: Woodson C. Merrel l M Uebf ax Page: 8/11 ILaltorp Patient Report Specimen ID: 257-480.2715-0 Acct 1:31 143092 Phone: Rte 68 Control a END31143092 Woodson Merrell EPSTEIN, JEFFREY 4-1E 67th St 9E 715TST New York NY 10065 NEWYORK NY 10021 tRrlhlheduPPhrddUllhhrnhrlllrllllllllhIdnlhll Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Age(y/m1d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 ID: Patient ID: Date reported: 09/18/2018 0610 ET NPt 1023153509 General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items Chlamydie/GC Amplificason, Panel 083935; HCV Ab w/Rflx to Verification; RPR, Rfx On RPR/Confirm TP TESTS RESULT FLAG LWITS REFERENCE INTERVAL LAE Chlemydia/GC Amplification Chlamydia trachomatis, NAA Negative Negative 01 Neisseria gonorrhoeae, NAA Negative Negative 01 Panel 083935 HIV Screen 4th Generation wRfx Non Reactive Non Reactive 01 HCV Lb w/Rflx to Verification HCV Ab c0.1 s/co ratio 0.0 - 0.9 01 Comment: 01 Non reactive HCV antibody screen is consistent with no HCV infection, unless recent infection is suspected or other evidence exists to indicate HCV infection. RPR, Rfx Qn APR/Confirm TP RPR Non Reactive Non Reactive 01 01 RN LabCorp Raritan Dir: Aracek B Reyes. MD 6$ First Avenue. Etonian, NJ 08869-1800 for equines. the physician may contact Branch: Lab: Date 'snitch:M/18M 1053 Er FINAL REPORT Pagel& 1 This document contains private and confidential health information tested by state and federal law. 01995.2018 Laboratory Corr/oleo of America. Flokengs It you here receivedthis docurmot in emb *me tali M RightsReeved-Enterprise Reran Version: 1O0 EFTA00299791 09/10/Z018 16:30 From: Woodson C. Merrel l 11 Uebfax Page: 9/11 Patient Report Specimen 10: 257-480-25424 Acct 31143092 Phone: Rte•. 68 ControlID: F5C31143092 Woodson Merrell EPSTEIN, JEFFREY 44 E 67th St 9E 715T ST New York NY 10065 NEW YORK NY 10021 Patient Details Specimen Details Physician Details DOB:01/20/1953 Date collected: 09/14/2018 1255 Local Ord:witty W MERRELL Age(y/m/d): 065/07/25 Date received: 09/15/2018 Refining: Gender: M SSN: Date entered: 09/15/2018 ID: MERRELL Patient ID: Date reported: 09/10/2018 082,3 ET Nit 1023153509 General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items Zinc. Whole Blood TESTS RESULT FLAG UNITS DEFERENCE :UTERI/AL LAB Zinc, Whole Blood 749 ug/dL 440 - 860 01 r 01 BN LabCorp Burlington 1447 York Court. Burlington, NC 27215-3381 Mr Wi11em F Hancock MO For inquiries. the physician may contact Branch: Lab: Date Issued 09/1snelos3 ET FINAL REPORT Page 1 or 1 This docament omelets private and confideraier health InformatOrt tected by state and federal bw. 0 1995.2O18 Laboratory Corporation of Afne*ae Holdings If you have feCifved this document in el for, please cell Ali Rights Reserved - Interprife Repoli Vetvorr 1.00 EFTA00299792 09/10/2018 16:38 From: Woodson C. Merrell M Webfax Page: 10/11 'ILabCorp Patient Report Specimen ID: 25/-480-23000 Acct a: 31143092 Phone Rte: 68 Control ID: 25648023000 Woodson Merrell EPSTEIN,JEFFREY 44 E 67th St 9EAST 71 STREET New York NY 10065 NYC NY 10021 qvillIrdurP444HdPIN400WPIPIQudel Patient Details Specimen Details Physician Details DOB:01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Age(y/m/d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 ID: MERRELL Patient ID: Date reported: 09/17/2018 2010 ET NPI: 1023153509 Ordered Items Heavy Metals Profile II, Blood TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Heavy Metals Profile II, Blood Lead, Blood Will Follow ug/dL 0 - 4 01 Blood Lead Collection Method: Venous Testing performed by Inductively coupled plasma/Mass Spectrometry. Environmental Exposure: WHO Recommendation <20 Occupational Exposure: OSHA Lead Std 40 BEI 30 Detection Limit is 1 Arsenic, Blood 8 ug/L 2 - 23 01 Detection Limit = 1 Mercury, Blood 2.1 ug/L 0.0 - 14.9 01 Environmental Exposure: <15.0 Occupational Exposure: BEI - Inorganic Mercury: 15.0 Detection Limit a 1.0 Cadmium, Blood None Detected ug/L 0.0 - 1.2 01 Environmental Exposure: Nonsmokers 0.3 - 1.2 Smokers 0.6 - 3.9 Occupational Exposure: OSHA Cadmium Std 5.0 BEI 5.0 Detection Limit a 0.5 01 BN LabCorp Burlington Dir: Wham F Hancock, MD 1447 York Court, Burlington, NC 27215-3361 For Inquiries. to physician may contact Branch: Lab: Date Issued: 05/18118 1053 ET PRELIMINARY REPORT Page 1 of This document contains private endconfidential heath inftwnstuian ted by state am fedetel kw. 0 1015-2018 Laboratory Corporation of Amencee Holdings It you have waived this docurrant error, please cal AI Rights Reserved • Entemtlw Report Venton: 100 EFTA00299793 09/18/2818 16:38 From: Woodson C. Merrell n Meninx rage: orn:l Mt.00 l% 44-7e I 00/17/2010 21:02 0442 GM /007 IMUGEN.Oxford Reference Diagnostic Division Immunotec, Inc. cVb/a IMUGEN 316 Norwood Park South. Norwood MA 02062 • • FAX Lyme Antibody Analysis Submkten Patient: WOODSON C MERRELL MD Name: JEFFREY EPSTEIN SUITE IB 44 EAST 67TH STREET Address: 9 EAST 71ST STREET NEW YORK NY 10021 NEW YORK NY 10066 D.O.B.: 0020/1953 Order rg Provide:: Submitter WOCDSON C MERRELL MD Record #: Account #: MERW IMUGEN Patient #: 2018013061 Antibody Capture Enzyme Immunoassay Immunoblot IgG (Western Blot) Test Date: PLASMA /* 1306 0W17/2018 Test Date: 0W17/2018 Results 8. bsrgctorlert639/40 8. burrkrksi49736 Antigen Antibody PLASMA 6 CSP 6 58 SS 880e/P41 13061 II Coned, owe. 0:00m Dean 41 C011Y2018 Olecoct PM Riteipi nee COMIOU B. burgdoeferi IIIM <1 49736 IgG <1 IfIA <I Wires felted the terathie amount ofB burpotriermarre#4# Normal Range: no rmcdy detected et <0.8 for IgM mai* #0#444.4 br lanckirrtinil and <1 for IgG and lgA. Comments: No IgM. IgG or IgA antibody to B. burgdorferi detected by cabbie Elk the IgG immunoblot results tel within normal lim its. Interpretation: No serologic evidence of infection with 8. burgdorferi (Lyme). Reactive bands la Eat m dD d 8. 0urgdorton antigens nth Mich IgG is reactive. Norval Range: Reactivity to <5 antigens on each blot Mabli aural